论文部分内容阅读
目的:探讨索拉非尼和沙利度胺这两种不同的化疗药物,对肝癌患者血清中VEGF-C、VEGF-D及微血管密度的影响。方法:将患者分成3组,每组16例。对照组采用常规治疗并服用安慰剂;索拉非尼和沙利度胺这两个组患者中,前者服用索拉非尼400 mg/次,2次/d,治疗6个月;后者服用沙利度胺每日服200mg,每周增加200mg/d,直至最大剂量每日600mg,至少服用4月。ELISA检测患者血清中VEGF-C、VEGF-D;免疫组织化学检测肝癌组织中微血管密度。结果:对照组患者血清中VEGF-C的水平为210ng/ml,索拉非尼组患者血清中VEGF-C的水平为132ng/ml,而沙利度胺组患者血清中VEGF-C的水平为186ng/ml。与对照组相比,索拉非尼组和沙利度胺组患者血清中VEGF-C的水平均降低。对照组患者血清中VEGF-D的水平为322ng/m1,索拉非尼组患者血清中VEGF-D的水平为217ng/ml,而沙利度胺组患者血清中VEGF-D的水平为256ng/ml。与对照组相比,索拉非尼组和沙利度胺组患者血清中VEGF-D的水平均降低。索拉非尼组患者血清中VEGF-D的水平明显低于沙利度胺高(P<0.05)。对照组肝癌组织MVD为(44.32±5.16)个,索拉非尼组患者肝癌组织MVD为(21.75±1.49)个,而沙利度胺组患者肝癌组织MVD为(34.78±2.31)个。结论:多靶点化疗药物索拉非尼对肝癌患者血清中VEGF-C、VEGF-D及微血管密度的影响最大,深入探讨其作用机制,可为其肝癌患者提供新的化疗方案。
Objective: To investigate the effects of sorafenib and thalidomide, which are two different chemotherapeutic drugs, on the serum levels of VEGF-C, VEGF-D and microvessel density in patients with liver cancer. Methods: The patients were divided into 3 groups, 16 cases in each group. The control group was treated with conventional therapy and placebo; the sorafenib and thalidomide patients in the two groups, the former taking sorafenib 400 mg / time, 2 times / d, for 6 months; the latter taking sand Liddle daily serving 200mg, weekly increase of 200mg / d, until the maximum daily dose of 600mg, taking at least April. Serum levels of VEGF-C and VEGF-D were detected by ELISA, and the density of microvessels in HCC tissues was detected by immunohistochemistry. Results: The level of VEGF-C in the serum of the control group was 210 ng / ml, the level of VEGF-C in the serum of the sorafenib group was 132 ng / ml, while the level of VEGF-C in the serum of the thalidomide group was 186ng / ml. Serum levels of VEGF-C were lower in the sorafenib and thalidomide groups compared with the control group. The level of VEGF-D in the serum of the control group was 322 ng / ml, the level of VEGF-D in the serum of the sorafenib group was 217 ng / ml, and the level of VEGF-D in the serum of the thalidomide group was 256 ng / ml. Serum levels of VEGF-D were lower in patients with sorafenib and thalidomide compared with those in the control group. The level of serum VEGF-D in patients with sorafenib was significantly lower than that with thalidomide (P <0.05). The MVD in control group was (44.32 ± 5.16), MVD in sorafenib group was (21.75 ± 1.49), while that in thalidomide group was (34.78 ± 2.31). Conclusion: Sorafenib, a multi-target chemotherapy drug, has the greatest influence on the serum levels of VEGF-C, VEGF-D and microvessel density in patients with hepatocellular carcinoma, and further explores its mechanism of action to provide new chemotherapy regimens for patients with liver cancer.